National Health Act 1953 Amendment special arrangements under subsection 100(1) Chemotherapy Pharmaceuticals Access Program (No. PB 132 of 2009) (Cth)

COMMONWEALTH OF AUSTRALIA

Instrument number PB 132 of 2009

Amendment special arrangements under subsection 100(1) of the National Health Act 1953

I, CHRIS BEDFORD, Acting Assistant Secretary, Access and Systems Branch, Department of Health and Ageing, delegate of the Minister for Health and Ageing, make this instrument under subsection 100(1) of the National Health Act 1953.

Dated 22 December 2009

CHRIS BEDFORD

Acting Assistant Secretary

Access and Systems Branch

Department of Health and Ageing

Amendment Special Arrangements — Chemotherapy Pharmaceuticals Access Program

1              Commencement

This instrument commences on 1 February 2010.

2              Amendment of PB 55 of 2009

Schedule 1 amends PB 55 of 2009.

Schedule 1   Amendments

[1]             Schedule 2, item dealing with Gemcitabine in the forms Powder for I.V. infusion
200 mg (as hydrochloride) and Powder for I.V. infusion 1 g (as hydrochloride)

insert in alphabetical order in the column headed “Brand”: Gemcitabine Ebewe

[2]             Schedule 2, item dealing with Irinotecan in the forms I.V. injection containing irinotecan hydrochloride trihydrate 40 mg in 2 mL, I.V. injection containing irinotecan hydrochloride trihydrate 100 mg in 5 mL, I.V. injection containing irinotecan hydrochloride trihydrate 300 mg in 15 mL and I.V. injection containing irinotecan hydrochloride trihydrate 500 mg in 25 mL

insert in alphabetical order in the column headed “Brand”: Irinotecan Ebewe

[3]             Schedule 2, item dealing with Mitozantrone in the form Injection 10 mg (as hydrochloride) in 5 mL

omit from the column headed “Brand”: Mitozantrone Ebewe